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Introduction 
Deeper understanding of the pathobiology of non-small cell lung cancer (NSCLC) has led to the 
development of small molecules that target genetic mutations known to play critical roles in the 
progression to metastatic disease. Mutations in epidermal growth factor receptor (EGFR), kirsten ras 
sarcoma oncogene (KRAS) and anaplastic lymphoma kinase (ALK) translocations are generally 
mutually exclusive in patients with NSCLC and the presence of one alteration in lieu of another can 
influence responses to targeted therapy. Thus, testing for these mutations and tailoring therapy 
accordingly is widely accepted as standard practice1,2,3.   
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ALK gene rearrangement in NSCLC was identified for the first time in a resected adenocarcinoma 
specimen from a 62-year-old male smoker. Rearrangements, either inversions or translocations, 
characterize the genomic disruptions involving ALK observed in NSCLC4,5. Inversions in the short arm 
of chromosome 2 that juxtapose echinoderm microtubule–associated protein-like 4 (EML4) 
with ALK and produce EML4-ALK–fusion tyrosine kinases4,6 are the most common noted changes but 
at least 27 fusion variants have been identified7. The reported prevalence of ALK rearrangements in 
unselected NSCLC is approximately 5%8,9. Remarkably, tumors with ALK rearrangements are addicted 
to ALK signalling and are inhibited by ALK Tyrosine Kinase Inhibitors (TKIs) in preclinical models10,11,12.  
In the past years several ALK inhibitors (ALKi) have been developed and become widely available in 
clinical practice; they are listed in table 1 with indication/approval along with the registration trials. 
Despite the efficacy of all these drugs, all ALK+ lung cancer patients will inevitably progress at some 
point during their treatment. To date, we are aware of two major mechanisms of resistance: ALK-
dependent (primary resistance, secondary acquired mutations, gene amplification) and ALK-
independent (by-pass signalling, drug efflux pump, epithelial-to-mesenchymal transition). 
Mechanisms of primary resistance are poorly understood and the spectrum of known secondary 
mutations mirrors Chronic Myeloid Leukemia (CML) and its mutational landscape acquired during 
imatinib treatment13.  
Unfortunately, the initial clinical response to targeted kinase inhibitors is almost always 
temporary, as acquired resistance to these drugs invariably develops. Many mechanisms of 
resistance to each targeted therapy have been identified, but can be generally categorized into 
two predominant classes: (1) alteration of the driver oncogene, (2) activation of a critical 
signalling pathway(s) in a parallel or downstream fashion, driving pro-survival signalling through 
different pathways.   
The most common and well established mechanism of resistance for the EGFR is the alteration of 
the driver oncogene, where the gatekeeper T790M mutation is found in ~50% of EGFR-mutant 
patients who become resistant to EGFR inhibition14,15 This has led to the development of several 
third-generation EGFR inhibitors, that could potentially block the growth of EGFR T790M-positive 
tumors16,17,18 
Unlike EGFR, type and frequency of ALK resistant mutations changes based on the inhibitor class. In 
crizotinib-refractory patients the most frequent mutations are L1196M and G1269A. The first is a 
classical gatekeeper mutation that alters the catalytic domain and causes resistance to ATP-
competitive inhibitors19, as in EGFR-T790M+ lung cancers. The latter, G1269A, determines a steric 
hindrance impairing the proper binding of crizotinib20. A plethora of less frequent mutations have 
been also described such as C1156Y, L1152R, 1151 T-ins at the N-terminus domain, I1171T, F1174L 
near the activation loop and G1202R, S1206Y in the solvent-exposed region close by the crizotinib 
binding-site21,22,23,24. Patients progressing on crizotinib treatment, regardless the presence of 
acquired mutations or not, seemed to be still ALK-dependent, as they respond to next-generation 
inhibitors, probably due to the limited ALK-blockade potency of crizotinib25.   
In large biopsies series from ALK+ NSCLC treated patients, the number of detected mutations 
increased after second generation ALKi26 and in one study were present in 56% of the entire 
cohort.42 For example, the rate of G1202R mutations increases from 2% in post-crizotinib treated 
patients to 43% in post-brigatinib cases highlighting a specific mutational profile associated to each 
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ALK TKI. The C1156Y mutation is less efficiently inhibited by ceritinib, contrary to the I1171T41 
mutation, identified in post-alectinib samples, that results sensitive to ceritinib. The gatekeeper 
mutation L1196M is inhibited by alectinib but emerges as a post-alectinib mutation itself; F1174L 
mutations determine resistance to ceritinib but are still sensitive to alectinib; the G1202R, most 
common mechanism of resistance post-second-generation ALKi (ceritinib, alectinib, brigatinib), is 
efficiently inhibited only by the third generation compound, lorlatinib, in preclinical models and 
patients42,. This scenario becomes even more complex if we add the presence of compound-related 
resistance mutations that emerge in patients treated with sequential ALK inhibitors: tumor clones 
harbouring E1210K/D1203N mutations after crizotinib and brigatinib remains sensitive only to 
lorlatinib42; on the other hand, a double mutant patient (C1156Y/L1198F) resistant to crizotinib, 
ceritinib and lorlatinib appeared to regain sensitivity to crizotinib, with a durable response27. 
If ALK gene amplification has been identified as resistance mechanism only in a small fraction (9%) of 
crizotinib refractory cases, multiple by-pass signalling tracks, which account for ≈40% of non-
mutated patients refractory to second-generation ALKi28, have been described: EGFR and HER family 
members activation29, also triggered by paracrine stimuli30, MET amplification [19], activation of 
downstream signalling pathway (i.e. RAS-MEK), even by specific MAP2K1 mutation that makes 
cancer cells sensitive to ALK/MEK co-inhibition31, c-KIT amplification requiring SCF [6], IGF-1R 
upregulation32 SRC activation47 and engagement of P2Y receptors33. Notably, efflux (MDR1 encoded) 
pump over-expression may be considered an alternative mechanism of resistance, as demonstrated 
in patients treated with crizotinib and ceritinib34, whose CNS penetration is hindered compared to 
alectinib that is not a substrate of this drug efflux system. 
Lastly, transition to a mesenchymal phenotype represents an alternative escape strategy. EMT has 
been described in post-ceritinib samples42 although the real contribution and underlying molecular 
mechanisms have not been elucidated yet. Some hypothesis came from the similar scenario of EMT 
in EGFR-mutant NSCLC in which alternative activation of AXL, IGF-1R or the SRC/FAK pathways have 
been proposed as causative molecular events35,36,37.  
 
 
 
 
ALKi testing, sequencing and best strategies 
 
The general consensus of the ATLAS IALSC Guidelines38 is that screening for ALK gene rearrangement 
should be performed for all patients with advanced NSCLC, mainly adenocarcinoma or with 
adenocarcinoma component. Depending on resources and academic interest, screening of patients 
with advanced NSCLC of other histologies should be considered, especially patients with one or 
more of these features: younger patient age, never/light smoking history, or negative results on 
testing for EGFR and KRAS mutations. ALK gene rearrangement may be found in tumors with non-
adenocarcinoma histologies, although this finding is rare39,40.  
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A re-biopsy at progression remains a practice extremely heterogeneous and not completely codified 
despite the fact that, if a secondary mutation is identified at progression, the tumour should be 
considered still ALK-dependent and the appropriate ALKi (figure 1) offered, based on the mutational 
sensitivity. This approach might give the opportunity to further control the cancer, delaying the use 
of the standard chemotherapy.  
It appears evident that the therapeutic landscape has been rapidly evolving and the future of ALK+ 
NSCLC treatment is promising with multiple therapeutic options over the past years as summarised 
in table 1.  
Crizotinib was the first ALK inhibitor that showed a benefit over the standard chemotherapy 
treatment in term of increased PFS in the second line setting, compared to chemotherapy in the 
Profile 100741 and in first line setting n the Profile 101442 compared to standard platinum based 
chemotherapy.  
Subsequently a different Alk inhibitor, Ceritinib, was developed and tested in several trails either in 
first line, similarly to the Profile 101442 design, within the Ascend 443 where ceritinib proved to be 
superior in term of  PFS compared to the standard first line chemotherapy treatment, either after 
progression to chemotherapy and to crizotinib in the Ascend 544 
Notably J-Alex trial first45 and the Alex trial46 later have showed the superiority of alectinib over 
crizotinib in term of PFS and time to central nervous system (CNS) progression in first line for this 
group of patients 
The J-ALEX trial, the first randomized phase III trial to directly compare two ALK inhibitors (alectinib 
versus crizotinib) in the first line setting41, was conducted exclusively in Japan at 41 study sites 
between November 2013 and August 2015 and 207 patients with stage IIIB/IV ALK positive NSCLC, 
who had previously received 0–1 lines of chemotherapy, but no prior ALK TKI, were enrolled and 
randomized to alectinib 300 mg twice daily or crizotinib 250 mg twice daily.  At the time of planned 
interim analysis, median PFS was not reached in the alectinib arm (20.3 months at the low end of the 
CI) and was 10.2 months in the crizotinib arm (HR 0.34, 99.7% CI 0.17–0.70). The ORR of alectinib in 
the intention to treat population was 85.4% (95% CI 78.6–92.3) versus 70.2% (95% CI 61.4–79) in the 
crizotinib arm. In the subgroup of patients with brain metastasis, there was also a strikingly 
improved response to alectinib (HR 0.08, 95% CI 0.01–0.61). For patients with brain metastatic 
lesions at baseline, the HR for the time to progression of a brain metastatic lesion or death was 0.16 
(95% CI 0.02–1.28), and for patients without brain metastatic lesions at baseline, the HR for the time 
to onset of a brain metastatic lesion or death was 0.41 (95% CI 0.17–1.01). All grade adverse events 
favored alectinib with the most common side effects in the alectinib arm. 
The results of this study were considered certainly compelling with some possible drawbacks: 
relatively large percentage of patients pre-treated with chemotherapy and a significantly larger 
percentage of patients with brain metastasis in the crizotinib arm compared to the alectinib one. 
The ALEX trial results were presented at ASCO 2017 with simultaneous publication in June 2017. It 
was an international phase III trial launched across 161 locations in 31 countries, with 303 treatment 
naïve ALK positive metastatic NSCLC patients randomized to alectinib 600 mg twice daily or crizotinib 
250 mg twice daily, with PFS again being the primary endpoint 42. Secondary endpoints included time 
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to CNS progression, ORR, DOR, OS, quality of life, and safety. After a follow up of 17.6 months in the 
crizotinib arm and 18.6 months in the alectinib arm, median PFS was not reached in the alectinib 
arm versus 11.1 months with crizotinib (HR 0.47, 95% CI 0.34–0.67, P<0.001). The effect was seen 
across nearly all subgroups with the exception of smokers and patients with an ECOG of 2, though 
these represented small numbers of patients. Time to CNS progression was also significantly longer 
with alectinib, with a 12-month incidence rate of CNS progression of 9.4% (95% CI 5.4–14.7) with 
alectinib versus 41.4% (95% CI 33.2–49.4) in the crizotinib arm. Among those patients with 
measurable CNS metastasis at baseline, 81% (95% CI 58–95) had a response in the alectinib arm 
versus 50% (95% CI 28–72) in the crizotinib arm, with 38% in the alectinib arm having achieved a 
complete response.  
The Alex trial was slightly different from the J-Alex: the study population included patients from 
multiple countries, the dose of alectinib used was 600 mg twice daily, all the patients were 
treatment naive, whereas those in the J-ALEX trial could have received chemotherapy initially. 
However the results of both trials closely mirrored each other and clearly demonstrated that in the 
frontline setting, alectinib is superior to crizotinib in terms of PFS, ORR, CNS response, and 
tolerability. 
Could we conclude, based on the evidence we have so far, that alectinib should be regarded as the 
new standard of care in first line or a sequential approach consisting of crizotinib first followed by 
alectinib could still be a preferable option?  Despite the fact that the OS data for both, J Alex and 
Alex trial, are not yet available, the magnitude of PFS benefit seems to suggest that using the more 
active drug, alectinib, up front could guarantee a better outcome particularly for its CNS activity and 
efficacy.  
Furthermore several ALKi (lorlatinib47, brigatinib48) have recently showed impressive results on naive 
and pre-treated ALK+ NSCLC patients increasing the number of therapeutical option available other 
than crizotinib in phase I-II trials. Thus, if the first line treatment seems to be relatively clear, the 
question “What to do next?” has become more than ever important and defining the optimal 
treatment strategy is the new task for the scientific community, even more than developing new 
ALKi. In the contest of correct sequencing, even if in a different clinical and genomic scenario, a 
possible answer might come from the APPLE-EORTC1603 trial49: a randomized, open-label, 
multicenter, 3-arm, phase II study in advanced, EGFR-mutant and EGFR-TKI-naive NSCLC patients, to 
evaluate the best strategy for sequencing gefitinib and osimertinib treatment. In all arms, a 
plasmatic ctDNA T790M test will be performed and the primary objective will be to evaluate the best 
strategy for sequencing of treatment with gefitinib and osimertinib in advanced NSCLC patients with 
common EGFR mutations, and to understand the value of liquid biopsy for the decision-making 
process. Even if on a different contest, the EGFR mutated patients, the result might point out that 
using the most effective TKI,  based exclusively on the increased PFS, might not be the best strategy 
and that sequencing carefully and properly the different and extremely active TKIs has to be 
carefully considered and it might offer a longer OS in the end.    
Although ongoing and future trials will be trying to establish the correct sequencing, we’d want to 
propose, based on the drugs development, the knowledge on mechanisms of primary and secondary 
resistance mutations that we already have, a possible treatment algorithm for ALK rearranged NCSLC 
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patients (figure1) stratified according to mutations detected throughout their clinical story by serial 
tissue or liquid biopsies performed at progression.   
Upfront and at relapse TKI combination might represent a valid strategy to delay or counteract, once 
appeared, ALK-independent by-pass track signalling pathways. Moreover permits to delay on-target 
resistance mechanisms, reducing the typical clonal pressure of single potent TKI monotherapy, like 
appearance of compound resistance mutations. Potential augmented toxicities of combined TKI 
politherapies may represent a major issue, partly curbed by reduced dosages or alternative drug 
schedules. Different strategies have been considered; EML4-ALK fusion proteins are known client of 
HSP90 chaperone machinery and therefore ganetespib demonstrated efficient control of ALK+ 
NSCLC either in presence or absence of ALK secondary mutations [54]. Even if not totally 
understood, this may be related to the wider HSP90 range of activities; parallel TRK (e.g. HER2) 
pathways, which sustain ALK+ cancer cells, are targeted by HSP90 and its inhibition contribute to 
shut down downstream signalling pathways. HSP90i alone or in combination with ALKi have been 
investigated (NCT01752400, NCT01712217). Powerful association of pan-HER and ALK inhibitors, 
supported by strong preclinical evidences50, had been limited by high-grade adverse events . 
ALK/MEK dual inhibition represents a promising therapeutic tool in order to up-front delay 
resistance mechanisms and improve response duration [56]. Also, MEK mutations appear in a 
ceritinib-treated patient and MEK inhibition contributes to disease control. Trametinib/ceritinib 
association is under evaluation (NCT03087448). MET amplification has been identified as post-
alectinib resistance mechanism and thus the specific patient responded to crizotinib treatment . 
Unfortunately, day to day practise might be, by far, different and more complex than what we have 
described here. In many European countries and in the United States of America the ALK treatment 
pathway is guided by labelling system and many ALKi are simply not available (table 2). Other than 
legislation issues and regulatory limitations, to make our algorithm even more challenging, is the fact 
that performing a re-biopsy at progression in many countries and institutes is not always possible or 
straight forward given the lack of staff, funding and facilities. Furthermore, even if the drugs were 
available, there isn’t consensus on the specific mutations to look for at progression, which makes 
even a re-biopsy possibly academic or not effective as it could be. 
At certain point all the ALK+ NSCLC will become ALK-independent and in these cases the patients 
could not benefit from another ALK inhibitors but standard chemotherapy51  or combination 
strategies ought to be considered.  
Future studies investigating alectinib-based combinations are already underway including 
combination with the programmed cell death ligand 1 (PD-L1) inhibitor atezolizumab and or 
bevacizumab. Integration with Immunotherapy (IO) seems limited by the fact that ALK+ tumors 
arose in patients with a low mutational load and PD-L1 and CD8 expressions are underrepresented 
[58]. Studies of these and other alectinib-based combinations should help to identify new 
therapeutic strategies that can overcome and even potentially prevent resistance. Patients lacking 
any traceable alteration or clinical-useful biomarker may be recruited for platinum-pemetrexed 
chemotherapy since ALK+ NSCLC appeared to be particularly sensitive to these therapies: 
pemetrexed association with crizotinib is object of current clinical evaluation (NCT02134912).  
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Conclusions 
Despite the improvement in the knowledge of resistance mechanisms and the efficacy of several 
ALKi, there are still hurdles to overcome: drug costs and/or local legislation narrow and limit the 
treatment option for this group of patients. Stronger collaborations between academia, 
pharmaceutical companies and regulatory authorities need to be spurred to implement availability 
and affordability of such drugs.  
Clinical trials are warranted to further investigate ALKi sequencing with a great interest to the EORTC 
1603 trial, to further understand the emerging resistance mechanisms after first-line alectinib and to 
develop possible strategies for delaying and overcoming these mechanisms.  
In conclusion we have summarized the evolution and improvement of ALK+ NSCLC patients 
treatment and highlighted, in this group of patients, a possible customized strategy, which would be 
potentially applicable and would represent a step towards personalized medicine.  
 
 
   
 
  
 
 
 
 
 
Table 1 (ALKi trials) 
Drug 
name 
Study Phase Population vs ORR IC-ORR PFS OS 
Crizotinib PROFILE 
1007 
III Platinum-
based 
chemotherapy 
pretreated 
(n = 347) 
 
Pemetrexed 
or docetaxel 
65% (95% 
CI 58–
72%) 
versus 
20% (95% 
CI 14–
26%; 
NA 7.7 versus 
3.0 months 
(HR, 0.49; 
95% CI 
0.37–0.64; 
p < 0.001) 
20.3 (95% 
CI 18.1–not 
reached) 
versus 22.8 
months 
(95% CI 
18.6–not 
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p < 0.001) 
 
 reached) 
(HR, 1.02; 
95% CI 
0.68–1.54; 
p = 0.54) 
 
Crizotinib PROFILE 
1014 
III Previously 
untreated 
(n = 343) 
Platinum 
plus 
pemetrexed 
74% (95% 
CI 67–
81%) 
versus 
45% (95% 
CI 37–
53%; 
p < 0.001) 
 
NA 10.9 versus 
7.0 months 
(HR, 0.45; 
95% CI 
0.35–0.60; 
p < 0.001 
 
Median OS 
was not 
reached in 
either group 
(HR for 
death with 
crizotinib, 
0.82; 95% 
CI 0.54–
1.26; 
p = 0.36) 
 
Ceritinib ASCEND
4 
III Previously 
untreated 
(n= 376) 
Platinum 
plus 
pemetrexed 
(72·5% 
[95% CI 
65·5–
78·7]) vs  
(26·7% 
[20·5–
33·7]) 
72.7% vs 
27% 
16.6 vs 8.1  
months 
(HR 
0.49; 95%  
0·37–0·64] 
p<0·00001 
NA 
Ceritinib ASCEND
5 
III Platinum-
based 
chemotherapy 
and crizotinib 
pretreated 
(n= 231) 
Pemetrexed 
or docetaxel 
39% vs 
7% 
 
35% vs 
5% 
5·4 vs 1.6 
months 
(HR 0·49 
[95% CI 
0·36–0·67]; 
p<0·0001 
18.1 vs 
20.1 
months not 
statistivaly 
significant.  
Ceritinib ASCEND 
8 
I 3 cohorts (267 
pts in total), 
121 treatment 
naive 
450 mg vs 
600 mg vs 
750 mg 
(SOC) 
78%, 75% 
and 70% 
NA 15 months 
PFS rate 
was 66.4%, 
58% and  
41%. 
NA 
Alectinib 
 
Global 
study 
II Crizotinib 
preteated 
Single arm 50% (95% 
CI, 41% 
to 59%) 
50% 8.9 months 
(95% CI, 
5.6 to 11.3 
months) 
NA 
Alectinib 
 
ALEX III Previously 
untreated 
(n= 303) 
Crizotinib 82.9% 
(95% CI 
85%-
76%) vs 
75.2 (95% 
67.8%-
82.1%  p 
< 0.01) 
81% vs 
50% 
25.7 vs 
10.4 
months 
(HR=0.50, 
95% CI, 
0.36-0.70; 
p<0.0001)  
NA 
Alectinib J-ALEX III Previously Crizotinib 85% (95% 80% vs 20.3 vs  NA 
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CI 78·6–
92·3) vs 
70% 
(61·4–
79·0  p < 
0.01) 
52% 10·2 (HR 
0·34 99·7% 
CI 0·17–
0·71, 
p<0·0001) 
Brigatinib NCT0144
9461 
I/II Previously 
Treated with 
crizotinib and 
naive  
(n= 79) 
Brigatinib  
(30-300 mg) 
71%  in 
crizotinib-
pretreated 
and 100% 
in 
crizotinib-
naive 
group 
53% 13.4 
months in 
pretreated 
crizotinib  
NA 
Brigatinib ALTA II Previously 
treated with 
crizotinib 
and/or 
chemotherapy 
(n= 222) 
Brigatinib 90 
g vs 180 mg 
48% 
(90mg), 
53% 
(180mg) 
51% and 
55% 
9.2 and 
16.7 
months 
NA 
Lorlatinib  NCT0197
0865  
II 6 cohorts  
including pts 
naive (275 in 
tot)  
Lorlatinib  90% 
(naive) 
75% 
(naive) 
NA NA 
Ensartinib NCT0276
7804 
III NA Crizotinib NA NA NA NA 
Entrectini
b  
NCT0209
7810 
I NA NA NA NA NA NA 
TPX-
0005 
 
NCT0309
3116 
I NA NA NA NA NA NA 
 
Table 2 (ALki approval)  
Active 
ingredient 
Indication Selection Dose FDA 
approval 
EMEA 
approval 
NICE 
approval 
Crizotinib ALK+ 
metastatic 
NSCLC 
 
VENTANA 
ALK (D5F3) 
CDx Assay 
Vysis ALK  
250 mg bid untreated patients untreated 
patients 
untreated 
patients 
Ceritinib ALK+ 
metastatic 
VENTANA 
ALK (D5F3) 
750 mg od untreated patients crizotinib 
pretreated 
crizotinib 
pretreated 
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NSCLC 
 
CDx Assay 
Vysis ALK 
patients patients 
Alectinib ALK+ 
metastatic 
NSCLC 
 
VENTANA 
ALK (D5F3) 
CDx Assay 
Vysis ALK 
600 mg bid untreated patients crizotinib 
pretreated 
patients 
MISSING 
(no evidence 
submission) 
Brigatinib ALK+ 
metastatic 
NSCLC 
 
VENTANA 
ALK (D5F3) 
CDx Assay 
Vysis ALK 
90 mg od for 
the first 7 
days;  
if tolerated, 
increase to 
180 mg od  
 
intolerant to or 
progressing on 
crizotinib 
MISSING MISSING 
Lorlatinib ALK+ 
metastatic 
NSCLC 
 
VENTANA 
ALK (D5F3) 
CDx Assay 
Vysis ALK 
100 mg od Breakthrough 
Therapy 
designation  - 
intolerant to or 
progressing on 
crizotinib 
 
MISSING MISSING 
Entrectinib ALK+ 
metastatic 
NSCLC 
 
VENTANA 
ALK (D5F3) 
CDx Assay 
Vysis ALK 
NA on going MISSING MISSING 
Ensartinib ALK+ 
metastatic 
NSCLC 
 
VENTANA 
ALK (D5F3) 
CDx Assay 
Vysis ALK 
NA on going MISSING MISSING 
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